Compare Fortinet Inc (FTNT) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs IDEXX Laboratories, Inc. — how do they compare? Fortinet Inc trades at $161.57 (market cap $118.78B), while IDEXX Laboratories, Inc. trades at $571.64 (market cap $46.22B). The key difference: Fortinet Inc is far larger — about 2.6× IDEXX Laboratories, Inc.'s market cap, and Fortinet Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| FTNT | IDXX | |
|---|---|---|
Market Cap | $118.78B | $46.22B |
Sector | Technology | Health |
52-Week High | $168.29 | $766.68 |
52-Week Low | $75.23 | $526.44 |
Enterprise Value | $115.21B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $164.09, down slightly by 0.07% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with revenue growing from $6.0B in 2024 to $6.8B in 2025 and net income reaching $1.85B. Recent Q2 2026 earnings beat expectations with $0.90 EPS versus $0.746 expected, continuing a pattern of strong quarterly performance. Analyst consensus remains positive with a $174.50 price target representing 6% upside potential from current levels.
Fortinet presents a compelling growth story with cybersecurity demand accelerating amid AI adoption, though elevated valuation metrics (P/E 57.2, P/S 16.08) require continued execution. Key risks include competitive pressures in the cybersecurity space and the stock's premium pricing relative to historical norms. The combination of strong earnings momentum, institutional support, and positive industry trends supports a constructive outlook for patient investors.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
